

Clinical Updates from San Antonio
Clinical Update #4: Triple-Negative Breast Cancer: Neoadjuvant/Adjuvant Immunotherapy

References

Tweet 2

Hofherr M, Hedgecorth J, Ademuyiwa F, et al. P3-06-06 Real-world analysis of adverse events of patients with triple negative breast cancer receiving therapy per KEYNOTE-522. Presented at: SABCS; December 7, 2022; San Antonio, TX. Accessed December 1, 2022.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer (v4.2022). Updated June 21, 2022. Accessed August 1, 2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. *N Engl J Med*. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651

Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. *N Engl J Med*. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549

Glossary

AE, adverse event
EFS, event-free survival
EHR, electronic health record
eTNBC, early triple-negative breast cancer
G, grade
HR, hazard ratio
imAE; immune-mediated adverse event
IO, immunotherapy
KN522, KEYNOTE-522
N+, node positive
OS, overall survival
pCR, pathologic complete response
Pembro, pembrolizumab
SOC, standard of care
T3/4, tumor >5 cm/any size with extension to the chest wall and/or skin
TNBC, triple-negative breast cancer
w/, with